133 related articles for article (PubMed ID: 8055765)
1. Famotidine in the management of gastro-oesophageal reflux.
Okoth FA; Lule GN; Ogutu EO; Pilczer S; Dubois C
East Afr Med J; 1994 Jan; 71(1):44-8. PubMed ID: 8055765
[TBL] [Abstract][Full Text] [Related]
2. [Symptomatic therapy with famotidine in non-erosive gastro-esophageal reflux. Results of an open multicenter study].
Heckers H; Lübbecke F
Arzneimittelforschung; 1995 Apr; 45(4):499-504. PubMed ID: 7779150
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of famotidine and omeprazole in healing symptoms of non-erosive gastro-oesophageal reflux disease: randomized-controlled study of gastro-oesophageal reflux disease.
Wada T; Sasaki M; Kataoka H; Tanida S; Itoh K; Ogasawara N; Oshima T; Togawa S; Kubota E; Yamada T; Mori Y; Fujita F; Ohara H; Nakao H; Sobue S; Joh T; Itoh M
Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():2-9. PubMed ID: 15943840
[TBL] [Abstract][Full Text] [Related]
4. Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease.
Fujiwara Y; Higuchi K; Nebiki H; Chono S; Uno H; Kitada K; Satoh H; Nakagawa K; Kobayashi K; Tominaga K; Watanabe T; Oshitani N; Arakawa T
Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():10-8. PubMed ID: 15943841
[TBL] [Abstract][Full Text] [Related]
5. Review article: Gastro-oesophageal reflux disease--application of the concept of complete remission.
Oudkerk Pool M
Aliment Pharmacol Ther; 2007 Dec; 26 Suppl 2():13-6. PubMed ID: 18081644
[TBL] [Abstract][Full Text] [Related]
6. Pathophysiological characteristics of the various forms of gastro-oesophageal reflux disease. Spectrum disease or distinct phenotypic presentations?
Frazzoni M; Manno M; De Micheli E; Savarino V
Dig Liver Dis; 2006 Sep; 38(9):643-8. PubMed ID: 16627016
[TBL] [Abstract][Full Text] [Related]
7. The extent of oesophageal acid exposure overlap among the different gastro-oesophageal reflux disease groups.
Shapiro M; Green C; Faybush EM; Esquivel RF; Fass R
Aliment Pharmacol Ther; 2006 Jan; 23(2):321-9. PubMed ID: 16393313
[TBL] [Abstract][Full Text] [Related]
8. Disease progression in gastro-oesophageal reflux disease as determined by repeat oesophageal pH monitoring and endoscopy 3 to 4.5 years after diagnosis.
McDougall NI; Johnston BT; Collins JS; McFarland RJ; Love AH
Eur J Gastroenterol Hepatol; 1997 Dec; 9(12):1161-7. PubMed ID: 9471021
[TBL] [Abstract][Full Text] [Related]
9. Natural history of gastro-oesophageal reflux disease without oesophagitis (NERD)--a reappraisal 10 years on.
Pace F; Bollani S; Molteni P; Bianchi Porro G
Dig Liver Dis; 2004 Feb; 36(2):111-5. PubMed ID: 15002817
[TBL] [Abstract][Full Text] [Related]
10. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group.
Carlsson R; Dent J; Watts R; Riley S; Sheikh R; Hatlebakk J; Haug K; de Groot G; van Oudvorst A; Dalväg A; Junghard O; Wiklund I
Eur J Gastroenterol Hepatol; 1998 Feb; 10(2):119-24. PubMed ID: 9581986
[TBL] [Abstract][Full Text] [Related]
11. Minimal change oesophagitis: a disease with characteristic differences to erosive oesophagitis.
Nakamura T; Shirakawa K; Masuyama H; Sugaya H; Hiraishi H; Terano A
Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():19-26. PubMed ID: 15943842
[TBL] [Abstract][Full Text] [Related]
12. Famotidine in the management of acid-reflux oesophagitis: a multicentre study.
Bovero E; Poletti M; Iaquinto G; Giardulo N; Zambelli A; Pisano G; Cheli R
Hepatogastroenterology; 1990 Dec; 37 Suppl 2():145-8. PubMed ID: 2083926
[TBL] [Abstract][Full Text] [Related]
13. Multivariate analysis of the association of acid and duodeno-gastro-oesophageal reflux exposure with the presence of oesophagitis, the severity of oesophagitis and Barrett's oesophagus.
Koek GH; Sifrim D; Lerut T; Janssens J; Tack J
Gut; 2008 Aug; 57(8):1056-64. PubMed ID: 18403496
[TBL] [Abstract][Full Text] [Related]
14. Routine management of gastro-oesophageal reflux disease by gastroenterologists in France: a prospective observational study.
Bretagne JF; Rey JF; Caekaert A; Barthélemy P
Dig Liver Dis; 2005 Aug; 37(8):566-70. PubMed ID: 15886080
[TBL] [Abstract][Full Text] [Related]
15. Evolution of gastro-oesophageal reflux disease over 5 years under routine medical care--the ProGERD study.
Malfertheiner P; Nocon M; Vieth M; Stolte M; Jaspersen D; Koelz HR; Labenz J; Leodolter A; Lind T; Richter K; Willich SN
Aliment Pharmacol Ther; 2012 Jan; 35(1):154-64. PubMed ID: 22070159
[TBL] [Abstract][Full Text] [Related]
16. Helicobacter pylori infection influences symptomatic response to anti-secretory therapy in patients with GORD--crossover comparative study with famotidine and low-dose lansoprazole.
Adachi K; Hashimoto T; Komazawa Y; Mihara T; Furuta K; Fujishiro H; Ishihara S; Amano Y; Hattori S; Kinoshita Y
Dig Liver Dis; 2005 Jul; 37(7):485-90. PubMed ID: 15975534
[TBL] [Abstract][Full Text] [Related]
17. Famotidine (20 mg) b.d. relieves gastrooesophageal reflux symptoms in patients without erosive oesophagitis. Famotidine/GERD Investigation Group.
Robinsen M; Decktor DL; Stone RC; Pevelery M; Barden P; Moyer R; Holt S; Root J; Hufnagel K; Humphries TJ
Aliment Pharmacol Ther; 1991 Dec; 5(6):631-43. PubMed ID: 1782306
[TBL] [Abstract][Full Text] [Related]
18. Nocturnal gastric acidity pattern in gastro-oesophageal reflux disease with or without oesophagitis.
Sozzi M; Valentini M; Poletti M; Bertolissi E; Serraino D; Bovero E; De Iaco F
Ital J Gastroenterol; 1995; 27(8):413-8. PubMed ID: 8775466
[TBL] [Abstract][Full Text] [Related]
19. [Intravenous treatment with quamatel in reflux-esophagus and erosive gastritis].
Ivanova S; Gavrilova V; Dimitrov L
Vutr Boles; 2000; 32(4):48-51. PubMed ID: 11688330
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy of gastrosidine (famotidine) in the treatment of gastroesophageal reflux at the reflux esophagitis stage].
Vasil'ev IuV; Li IA
Eksp Klin Gastroenterol; 2002; (4):30-3, 131. PubMed ID: 12503271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
